RiaSTAP
| Product Specs | Description |
|---|---|
| Manufacturer Name | CSL Behring |
| Indications | For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia |
| Contraindications | Anaphylactic or severe reactions to RiaSTAP or its components. Not indicated for dysfibrinogenemia |
| Viral Safety Process | FDA-licensed serological assays, nucleic acid testing |
| Product Half-Life | Adults 82.3 ± 20.0 hours Children 69.9 ± 8.5 hours |
| Manufacturing Method | Cryoprecipitate into a glycine precipitate, which is then further purified by multiple precipitation/adsorption steps |
| Storage Requirements/Shelf Life |
|
| Nominal Vial Size & Diluent Volume | 900 mg to 1300 mg/50 mL |